Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|EA2174||ECOG-ACRIN||A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA8191||ECOG-ACRIN||Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence||Adult CIRB - Late Phase Emphasis||Available to Open|
|N0577||NCCTG||N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACOSOG-Z1041||ACSOG||A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients with HER-2 Positive Operable Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GY005||NRG||A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone; or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian; fallopian tube; or primary peritoneal cancer (COCOS)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031201||Alliance||Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide; Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A091605||Alliance||A Randomized Phase II Study of anti-PD1 antibody [MK-3475 (pembrolizumab)] alone versus anti- PD1 antibody plus Stereotactic Body Radiation therapy in advanced Merkel Cell Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|E2100||ECOG||A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-49808||CALGB||A 2 X 2 X 2 Factorial Randomized Phase III Trial of Multimodality Therapy Comparing 4 Cycles of Doxorubicin and Cyclophosphamide with or without Dexrazoxane (AC +/- Z) Followed by 12 Weeks of Weekly Paclitaxel with or without Trastuzumab (T H) Followed by Local Therapy Followed by 40 Weeks of Weekly Trastuzumab or none in Women with HER-2+ STAGE IIIA; IIIB or Regional Stage IV Breast Cancer **ADMINISTRATIVELY COMPLETED as of December 15; 2002**||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-40302||CALGB||Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized; Double-Blind; Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|